Literature DB >> 28670833

Modeling time-to-event (survival) data using classification tree analysis.

Ariel Linden1,2, Paul R Yarnold3.   

Abstract

RATIONALE, AIMS, AND
OBJECTIVES: Time to the occurrence of an event is often studied in health research. Survival analysis differs from other designs in that follow-up times for individuals who do not experience the event by the end of the study (called censored) are accounted for in the analysis. Cox regression is the standard method for analysing censored data, but the assumptions required of these models are easily violated. In this paper, we introduce classification tree analysis (CTA) as a flexible alternative for modelling censored data. Classification tree analysis is a "decision-tree"-like classification model that provides parsimonious, transparent (ie, easy to visually display and interpret) decision rules that maximize predictive accuracy, derives exact P values via permutation tests, and evaluates model cross-generalizability.
METHOD: Using empirical data, we identify all statistically valid, reproducible, longitudinally consistent, and cross-generalizable CTA survival models and then compare their predictive accuracy to estimates derived via Cox regression and an unadjusted naïve model. Model performance is assessed using integrated Brier scores and a comparison between estimated survival curves.
RESULTS: The Cox regression model best predicts average incidence of the outcome over time, whereas CTA survival models best predict either relatively high, or low, incidence of the outcome over time.
CONCLUSIONS: Classification tree analysis survival models offer many advantages over Cox regression, such as explicit maximization of predictive accuracy, parsimony, statistical robustness, and transparency. Therefore, researchers interested in accurate prognoses and clear decision rules should consider developing models using the CTA-survival framework.
© 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  censoring; classification tree analysis; machine learning; survival

Mesh:

Substances:

Year:  2017        PMID: 28670833     DOI: 10.1111/jep.12779

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  12 in total

1.  Use of Machine Learning for Prediction of Patient Risk of Postoperative Complications After Liver, Pancreatic, and Colorectal Surgery.

Authors:  Katiuscha Merath; J Madison Hyer; Rittal Mehta; Ayesha Farooq; Fabio Bagante; Kota Sahara; Diamantis I Tsilimigras; Eliza Beal; Anghela Z Paredes; Lu Wu; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-08-05       Impact factor: 3.452

2.  Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma.

Authors:  Zihao Wang; Lu Gao; Xiaopeng Guo; Chenzhe Feng; Wei Lian; Kan Deng; Bing Xing
Journal:  Aging (Albany NY)       Date:  2019-12-17       Impact factor: 5.682

3.  Integrated analysis of serum lipid profile for predicting clinical outcomes of patients with malignant biliary tumor.

Authors:  Lejia Sun; Xin Ji; Dongyue Wang; Ai Guan; Yao Xiao; Haifeng Xu; Shunda Du; Yiyao Xu; Haitao Zhao; Xin Lu; Xinting Sang; Shouxian Zhong; Huayu Yang; Yilei Mao
Journal:  BMC Cancer       Date:  2020-10-09       Impact factor: 4.430

4.  The dangerous and contradictory prognostic significance of PVR<3WU when TAPSE<16mm in postcapillary pulmonary hypertension.

Authors:  Olivier Raitière; Emmanuelle Berthelot; Charles Fauvel; Pierre Guignant; Nassima Si Belkacem; Olivier Sitbon; Fabrice Bauer
Journal:  ESC Heart Fail       Date:  2020-07-23

5.  Identification of mortality-risk-related missense variant for renal clear cell carcinoma using deep learning.

Authors:  Jin-Bor Chen; Huai-Shuo Yang; Sin-Hua Moi; Li-Yeh Chuang; Cheng-Hong Yang
Journal:  Ther Adv Chronic Dis       Date:  2021-02-15       Impact factor: 5.091

6.  Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Authors:  Konstantinos Liapis; Vasileios Papadopoulos; George Vrachiolias; Athanasios G Galanopoulos; Menelaos Papoutselis; Sotirios G Papageorgiou; Panagiotis T Diamantopoulos; Vassiliki Pappa; Nora-Athina Viniou; Alexandra Kourakli; Dimitris Τsokanas; Theodoros P Vassilakopoulos; Eleftheria Hatzimichael; Eleni Bouronikou; Maria Ximeri; Charalambos Pontikoglou; Aekaterini Megalakaki; Panagiotis Zikos; Panayiotis Panayiotidis; Maria Dimou; Stamatis Karakatsanis; Maria Papaioannou; Anna Vardi; Flora Kontopidou; Nikolaos Harchalakis; Ioannis Adamopoulos; Argiris Symeonidis; Ioannis Kotsianidis
Journal:  Blood Cancer J       Date:  2021-02-11       Impact factor: 11.037

7.  Comprehensive In Silico Analysis of a Novel Serum Exosome-Derived Competitive Endogenous RNA Network for Constructing a Prognostic Model for Glioblastoma.

Authors:  Zihao Wang; Xin Ji; Lu Gao; Xiaopeng Guo; Wei Lian; Kan Deng; Bing Xing
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

8.  A Novel S100 Family-Based Signature Associated with Prognosis and Immune Microenvironment in Glioma.

Authors:  Yifang Hu; Jiahang Song; Zhen Wang; Jingbao Kan; Yaoqi Ge; Dan Wang; Rihua Zhang; Wensong Zhang; Yun Liu
Journal:  J Oncol       Date:  2021-09-29       Impact factor: 4.375

Review 9.  Risk Prediction of Cardiovascular Events by Exploration of Molecular Data with Explainable Artificial Intelligence.

Authors:  Annie M Westerlund; Johann S Hawe; Matthias Heinig; Heribert Schunkert
Journal:  Int J Mol Sci       Date:  2021-09-24       Impact factor: 5.923

10.  An Autophagy-Related Gene Signature Associated With Clinical Prognosis and Immune Microenvironment in Gliomas.

Authors:  Yang Xu; Renpeng Li; Xiaoxia Li; Naijun Dong; Di Wu; Lin Hou; Kan Yin; Chunhua Zhao
Journal:  Front Oncol       Date:  2020-10-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.